使用恩瑞格要注意哪些事项？

The chemical name is 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid. Enrig is an iron chelator product developed by the Swiss pharmaceutical company Novartis. Enrig is the first oral iron-depleting agent approved by the U.S. FDA for routine use. It is approved for use in patients ≥2 years old with chronic iron overload caused by blood transfusion. In Europe, it is recommended as 6 As a first-line drug for patients with thalassemia iron overload over the age of 18, clinical research is currently underway in China; Phase II and III clinical trials and pharmacokinetic studies have shown that it has good safety and tolerability, can significantly reduce iron load in the heart and liver, and is easily accepted by patients. At the same time, it also has pharmaceutical properties such as antifungal (such as Mucor growing in an iron-rich environment, anti-cell proliferation, anti-malarial, anti-oxidative stress damage, anti-cytotoxic-induced apoptosis), etc.; it can be used for the treatment of secondary hemochromatosis, porphyria cutanea tarda and other diseases.

DFS is a tridentate iron chelator. DFS has pharmacological effects such as antifungal effects (such as Mucor mold growing in an iron-rich environment), anti-cell proliferation, anti-malaria, anti-oxidative stress damage, anti-cytotoxicity-induced apoptosis, etc.

1. DFS and fungal infection: Iron is a substance that fungi rely on for survival, and it plays a very important role in the growth and toxicity of fungi. The antifungal effect of iron chelators may lie in their removal of iron necessary for fungal growth, thereby achieving the purpose of treating fungal infections.

2. DFS and cell proliferation: Iron plays a very important role in the process of cell proliferation, and iron chelators may have anti-cell proliferation properties. This suggests that iron chelators may become a new type of anti-cancer agent for the treatment of tumors.

What should you pay attention to when using it? 1. Enriga may cause a rash. Generally, the rash will disappear automatically without the need to adjust the dosage or stop the medication. If the condition is severe or persistent, the medication should be stopped. 2. The patient's vision or hearing may be affected. 3. It should be taken 30 minutes before meals. 4. It should be taken at the same time every day.